Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Docetaxel/Capecitabine and AC in Breast Cancer
NCT00005908Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jun 2000
- Primary completion
- Jan 2008
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of docetaxel, capecitabine in breast cancer, sponsored by National Cancer Institute. Started Jun 2000; status: completed.
02
Drugs
docetaxelcapecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00005908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005908.